• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PetVivo Holdings Inc. (Amendment)

    5/15/24 7:21:23 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care
    Get the next $PETV alert in real time by email
    SC 13G/A 1 sc13g-amend.htm AMENDMENT NO. 3 TO SCHEDULE 13G

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    PetVivo Holdings, Inc.

    (Name of Issuer)

     

    Common Stock, (Nasdaq: PETV)

    (Title of Class of Securities)

     

    716817408

    (CUSIP Number) 

     

    April 29, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐  Rule 13d-1(b)
       
    ☒  Rule 13d-1(c)
       
    ☐  Rule 13d-1(d)
       

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No. 716817408 SC 13G/A Page 2 of 5 Pages

     

    1

     

    NAME OF REPORTING PERSON

     

    A.L. Sarroff Fund, LLC [1] 

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ☐

    (b)   ☐ 

    3

     

    SEC USE ONLY 

     

    4

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States 

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

     

    SOLE VOTING POWER

     

    2,718,544 common stock [2] 

     

    6

     

    SHARED VOTING POWER

     

    0 

     

    7

     

    SOLE DISPOSITIVE POWER

     

    2,718,544 common stock [2] 

     

    8

     

    SHARED DISPOSITIVE POWER

     

    0 

    9

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,718,544 common stock [2] 

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐ 

    11

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    16.21% [3] 

    12

     

    TYPE OF REPORTING PERSON

     

     PN [4]

     

     

    [1] A.L. Sarroff Fund, LLC (the "Company") is a New York Limited Liability Company (LLC) whose two individual members own, respectively, 90% and 10% of the Company's membership interests. The securities reported in this Schedule 13G were acquired primarily in accounts in the name of the Company and partly in accounts in the names of the two individual members.

    [2] In addition to the common shares reported in this Schedule 13G, the Company owns and/or controls 2,138,696 Warrants of the issuer. The Warrants are exercisable on the following schedule: $1,166,000.00 exercisable as of August 4, 2026, 111,000 exercisable as of December 6, 2026, and 861,696 as of April 29, 2027. These Warrants have not been exercised. Pursuant to SEC Rule 13d-3(d) (1), these Warrants are therefore not included in the Company's aggregate shareholdings for purposes of this Schedule G.

    [3] According to the issuer's latest Form 10-Q, there were 16,770,018 outstanding common shares as of December 31, 2023. The common shares owned and/or controlled by the Company as of December 31, 2023 totaled 16.21% of the common shares outstanding. 

    [4] This filing is made in reliance upon SEC Rule 13d-1(c). The Company, (a) has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b); (b) is not a person reporting pursuant to SEC Rule 13d-1(b)(1); and (c) is not directly or indirectly the beneficial owner of 20 percent of more of the class. 

     
     
     

     

    CUSIP No. 716817408 SC 13G/A Page 3 of 5 Pages

     

      Item 1(a). NAME OF ISSUER:

             

                          The name of the issuer is PetVivo Holdings, Inc.

     

      Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

                            
                          5251 Edina Industrial Blvd., Edina, Minnesota, 55349.

     

      Item 2(a). NAME OF PERSON FILING:

                         
                          A.L. Sarroff Fund, LLC .

     

      Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

             

                          43 Meadow Woods Road, Great Neck, NY 11020

      Item 2(c). CITIZENSHIP:

             

                         United States.

     

      Item 2(d). TITLE OF CLASS OF SECURITIES:

             

                         Common stock.

     

      Item 2(e). CUSIP NUMBER:


                        716817408                                 

     

      Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a)   ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b)   ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c)   ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d)   ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

      (e)   ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

      (f)   ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g)   ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h)   ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i)   ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:___.

     

     
     
     

     

    CUSIP No. 716817408 SC 13G/A Page 4 of 5 Pages

     

      Item 4. OWNERSHIP

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)   Amount beneficially owned: 2,718,544 common stock

     

    (b)   Percent of class: 16.21%

     

    (c)   Number of shares as to which such person has:

     

      (i)   Sole power to vote or to direct the vote    2,718,544 common stock

     

      (ii)   Shared power to vote or to direct the vote    0

     

      (iii)   Sole power to dispose or to direct the disposition of  2,718,544 common stock

     

      (iv)   Shared power to dispose or to direct the disposition of     0

     

      Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.


    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [ ].

    Not applicable.

     

      Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

            

    Not applicable.

     

      Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.

             

    Not applicable.

     

      Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

      Item 9. NOTICE OF DISSOLUTION OF GROUP.

             

    Not applicable.

     

      Item 10. CERTIFICATION.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

    CUSIP No. 716817408 SC 13G/A Page 5 of 5 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      

    A.L. Sarroff Fund, LLC

     

     

    /s/ Alan L. Sarroff  
    Alan L. Sarroff  
    Title: Chief Executive Officer and Managing Member  

      

     

    DATED: May 13, 2024 

     

     

     

     

     

     

    Get the next $PETV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PETV

    DatePrice TargetRatingAnalyst
    10/12/2021$7.00Buy
    ThinkEquity
    More analyst ratings

    $PETV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lai John bought $90,000 worth of shares (150,000 units at $0.60), increasing direct ownership by 13% to 1,288,592 units (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    4/17/24 5:28:07 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Lai John was granted 84,375 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    9/22/25 11:25:05 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Lowenthal Garry N was granted 79,375 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    9/22/25 11:23:17 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Director Jasper Joseph William was granted 17,905 shares, increasing direct ownership by 26% to 87,659 units (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    8/11/25 6:15:19 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ThinkEquity initiated coverage on PetVivo Holdings with a new price target

    ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00

    10/12/21 11:03:37 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    SEC Filings

    View All

    PetVivo Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Entry into a Material Definitive Agreement

    8-K - PetVivo Holdings, Inc. (0001512922) (Filer)

    9/30/25 6:03:45 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PetVivo Holdings Inc.

    SCHEDULE 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    7/28/25 10:47:08 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by PetVivo Holdings Inc.

    10-K - PetVivo Holdings, Inc. (0001512922) (Filer)

    7/10/25 5:06:51 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Leadership Updates

    Live Leadership Updates

    View All

    PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

    Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t

    6/6/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor

    PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts. For the past 20 years, Mr. Eldred served as President of North American Operations for Dech

    1/27/25 9:29:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide

    MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW))), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. "Cindy's experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals," PetVivo CEO, John Lai. "Her experience with other veterinary products and her knowledge of clinic operations enables her to prioritize and better address the veterinarians and cli

    10/21/24 9:45:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT

    MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for horses, dogs and other companion animals announced today that the Company has recently entered into note conversion agreements ("Conversion Agreements") with four existing shareholders of the Company to convert the outstanding balances of fourteen promissory notes ("Notes") having an aggregate debt outstanding of $2,018,155 consisting of principal amount of $1.850,000, plus total accr

    9/30/25 11:33:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Animal Health Expands Veterinary Education with New RACE-Approved CE Courses on Osteoarthritis and Regenerative Therapies

    On-demand programs deliver clinically relevant science, technical instruction, and case applications in small animal and equine practice MINNEAPOLIS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, a subsidiary of PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)) and a veterinary medical device company pioneering intra-articular and regenerative solutions, announces the launch of three new continuing education (CE) courses for veterinary professionals. Each RACE-approved program (1.0 credit hour) is designed to help veterinarians deepen their expertise in osteoarthritis (OA), joint injection techniques, and regenerative modalities for canine and equine patients. The courses -

    9/25/25 1:49:32 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

    NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through September 23. Please schedule 1x1 meetings here September 18th PresentationTicker(s)Amplia Therapeutics Limited(OTC:INNMF, ASX: ATX))Kelyniam Global, Inc.(O

    9/18/25 8:35:00 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $PETV
    Financials

    Live finance-specific insights

    View All

    PetVivo Reports Fiscal Q1 2026 Results

    MINNEAPOLIS, MN, US, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX:PETV, OTC ID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported results for its first quarter of fiscal year 2026 ended June 30, 2025. All comparisons are to the previous year first quarter period ending June 30, 2024, unless otherwise noted. The company will hold a conference call today, August 14, 2025, at 5:00 p.m. Eastern time to discuss the results for the quarter, followed by a question-and-answer session (see dial-in information below). Fiscal Q1

    8/14/25 4:40:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Sets Fiscal First Quarter 2026 Conference Call for Thursday, August 14, 2025 at 5:00 p.m. ET

    MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2025. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question-and-answer period. The Fiscal First Quarter 2026 conference call information is as follows: Date: Thursday, August 14, 2025 Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific t

    8/7/25 12:45:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Reports Fiscal 2025 Results

    MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB:PETV, OTC:PETVW), a leading biomedical company delivering innovative medical therapeutics for equines and companion animals, reported results for its fiscal year ended March 31, 2025. All comparisons are to the previous fiscal year period unless otherwise noted. The company has filed for an extension for the filing of its Form 10-K for the fiscal year ending March 31, 2025, therefore all financial results reported in this press release are unaudited preliminary estimates, and are subject to change. The company will hold a conference call today at

    6/30/25 4:10:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $PETV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PetVivo Holdings Inc.

    SC 13G - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/4/24 1:57:37 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    10/1/24 5:26:09 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care